Disclosures: Nicholas Prescott: Nothing to Disclose, Andres Mansisidor: Nothing to Disclose, Yaron Bram: Nothing to Disclose, Christine Lim: Nothing to Disclose, Viviana Risca: Nothing to Disclose, Yael David: Nothing to Disclose, Robert Schwartz: Miromatrix Inc: Advisor, Lime Therapeutics: Advisor, Otsuka Inc.: Grant/Research Support, Alnylam Pharmaceuticals: Speaking and Teaching, Alnylam Pharmaceuticals: Consultant 722 IMPROVEMENTS IN PRURITUS ARE ASSOCIATED WITH IMPROVEMENTS IN GROWTH IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM THE MARCH-ON TRIAL Alexander Miethke 1 Amal Aqul 2 Chuan-Hao Lin 3 Douglas Mogul 4 Tiago Nunes 4 Jolan Terner-Rosenthal 4 Marshall Baek 4 Pamela Vig 4 Richard Thompson 5 , 1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2 University of Texas Southwestern Medical Center, Dallas, Texas, 3 Children's Hospital Los Angeles, Los Angeles, California, 4 Mirum Pharmaceuticals, Inc., Foster City, California, 5 King's College London, United Kingdom Background: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders resulting in disrupted bile composition and cholestasis leading to debilitating pruritus, growth deficits, vitamin deficiency, and progressive liver damage
Portions are good, flavor is good, and if I need more flavor I either add "no salt" (i need to restrict salt) or some cajun or blackened seasoning
Over the past few years, the conversation around GLP-1 receptor agonists has been dominated by extremes: dramatic weight loss in clinical trials, before-and-after transformations on social media, and a public discourse that has oscillated between miracle and backlash
Inadequate glycaemic control alongside persistent hunger is particularly important to address
Lead- and drug-like compounds: the rule-of-five revolution
What Are the Common Side Effects of Ozempic
